Navigation Links
Harmless soil-dwelling bacteria successfully kill cancer
Date:9/4/2011

A bacterial strain that specifically targets tumours could soon be used as a vehicle to deliver drugs in frontline cancer therapy. The strain is expected to be tested in cancer patients in 2013 says a scientist at the Society for General Microbiology's Autumn Conference at the University of York.

The therapy uses Clostridium sporogenes a bacterium that is widespread in the soil. Spores of the bacterium are injected into patients and only grow in solid tumours, where a specific bacterial enzyme is produced. An anti-cancer drug is injected separately into the patient in an inactive 'pro-drug' form. When the pro-drug reaches the site of the tumour, the bacterial enzyme activates the drug, allowing it to destroy only the cells in its vicinity the tumour cells.

Researchers at the University of Nottingham and the University of Maastricht have now overcome the hurdles that have so far prevented this therapy from entering clinical trials. They have introduced a gene for a much-improved version of the enzyme into the C. sporogenes DNA. The improved enzyme can now be produced in far greater quantities in the tumour than previous versions, and is more efficient at converting the pro-drug into its active form.

A fundamental requirement for any new cancer therapy is the ability to target cancer cells while excluding healthy cells. Professor Nigel Minton, who is leading the research, explains how this therapy naturally fulfils this need. "Clostridia are an ancient group of bacteria that evolved on the planet before it had an oxygen-rich atmosphere and so they thrive in low oxygen conditions. When Clostridia spores are injected into a cancer patient, they will only grow in oxygen-depleted environments, i.e. the centre of solid tumours. This is a totally natural phenomenon, which requires no fundamental alterations and is exquisitely specific. We can exploit this specificity to kill tumour cells but leave healthy tissue unscathed," he said.

The research may ultimately lead to a simple and safe procedure for curing a wide range of solid tumours. "This therapy will kill all types of tumour cell. The treatment is superior to a surgical procedure, especially for patients at high risk or with difficult tumour locations," explained Professor Minton. "We anticipate that the strain we have developed will be used in a clinical trial in 2013 led by Jan Theys and Philippe Lambin at the University of Maastricht in The Netherlands. A successful outcome could lead to its adoption as a frontline therapy for treating solid tumours. If the approach is successfully combined with more traditional approaches this could increase our chance of winning the battle against cancerous tumours."


'/>"/>

Contact: Laura Udakis
l.udakis@sgm.ac.uk
44-118-988-1843
Society for General Microbiology
Source:Eurekalert  

Related medicine news :

1. Not All Birthmarks Harmless, Expert Says
2. Sex between adolescents in romantic relationships is often harmless to their academics
3. Harmless Brain Abnormalities in Kids Pose Disclosure Dilemmas
4. Color, Odor Changes in Urine Usually -- But Not Always -- Harmless, Reports Harvard Women's Health Watch
5. Babies Born With Heart Disease Often Harmed by Gut Bacteria
6. Dangerous Bacteria Hide Out in Nurses, Doctors Uniforms
7. UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug
8. Bacterial Strain Behind Black Death Plague Is Likely Extinct: Study
9. Study: Afghan patients a common source of drug-resistant bacteria
10. New Bacteria Linked to Tattoo Infections
11. Are Kids Brown-Bagging Bacteria?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Harmless soil-dwelling bacteria successfully kill cancer
(Date:5/31/2016)... ... 31, 2016 , ... The successful implementation of “lean manufacturing” in various fields ... laboratories have different challenges compared to manufacturing environments. , In order to provide ... TOLEDO has developed the Lean Lab Checklist . This checklist will help users ...
(Date:5/31/2016)... ... May 31, 2016 , ... In ... can describe personality traits in humans. Using presidential candidate Donald Trump as an ... vitality. , “AstroNumerology is not about adding numbers up,” says Kalsi. “It ...
(Date:5/31/2016)... ... ... Phynd Technologies, Inc. announced recently the signing of three new hospitals: Meadows ... Center – Somers Point, NJ. The new clients range in bed size from 57 ... Phynd’s solution and its interoperability. , Houston Methodist is a leading academic medical center ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Dr. Charles ... and Dentistry of New Jersey in the class of 1986, where he graduated in ... dentistry at his current location in Livingston since 1989. He has been a member ...
(Date:5/31/2016)... Washington, NY (PRWEB) , ... May 31, 2016 , ... ... other essential nutrients to on the go individuals and dedicated athletes, continues to transform ... , Loaded with whey, pea and milk protein, branched-chain amino acids (BCAA), alkaline ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... RnRMarketResearch.com adds "Asthma - Pipeline ... of Asthma therapy at various stages, therapeutics assessment by ... (RoA) and molecule type, along with latest updates, and ... players involved in the therapeutic development for Asthma and ... Complete report on H1 2016 pipeline review of Asthma ...
(Date:5/30/2016)... 2016 According to ... Market by Technology (Single-factor (Fingerprint, Face, Iris, ... (Workforce Management), End User (Hospitals, Healthcare Institutions) ... MarketsandMarkets, the market is projected to reach ... 1,182.6 Million by 2016, at a CAGR ...
(Date:5/30/2016)... May 30, 2016 The ... USD 7.3 billion by 2024, according to a ... increasing natality rate, the growing malnutrition coupled with ... and gastro-intestinal tract diseases are expected to boost ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
Breaking Medicine Technology: